Dynalabs LLC, Saint Louis, MO
Is Dynalabs LLC registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Dynalabs LLC hold a Missouri pharmacy license?
State board of pharmacy records for Missouri are not checked: the Division of Professional Registration’s license downloads sit on a script-driven portal, and its robots.txt file disallows the board’s pharmacy pages.
Has Dynalabs LLC had a state board action or FDA letter?
FDA letters: no matching record found on FDA’s compounding inspections and actions page (current as of Oct 22, 2026, covering 2019 on) on Nov 15, 2026; the page lists 1 Form 483 (Sep 26, 2019) for Dynalabs LLC. State board of pharmacy records for Missouri are not checked: the Division of Professional Registration’s license downloads sit on a script-driven portal, and its robots.txt file disallows the board’s pharmacy pages.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Dynalabs LLC
- Location
- Saint Louis, MO
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Sep 26, 2019
- FDA Data Dashboard inspections
- 3 inspections: 2 VAI, 1 NAI; 2 published Form 483s
- Form 483 text on this page
- 1 Form 483, 4 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Dynalabs LLC, a 503A facility, with 1 dated action.
| Document | |||
|---|---|---|---|
| Sep 26, 2019 | Form 483 | 483 Issued 09/26/2019 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Dynalabs LLC, Saint Louis, MO (FEI number 3005115360), matched to this page by exact name, city and state. It lists 3 inspections: 2 VAI, 1 NAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Sep 26, 2019 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3005115360 | 1103093 |
| Jun 12, 2014 | No Action Indicated (NAI) | Drug Quality Assurance (Drugs) | 3005115360 | 883544 |
| Nov 13, 2012 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3005115360 | 808001 |
Form 483s FDA has published for this site
- Sep 26, 2019: Form 483 to Dynalabs LLC, published Feb 24, 2020. fda.gov
- Oct 29, 2015: Form 483 to Dynalabs LLC, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 4 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Sep 9, 2019 to Sep 26, 2019: 4 observations
- Firm on the cover
- Dynalabs LLC, 2327 Chouteau Ave, Saint Louis, MO 63103-3010
- FEI number
- 3005115360
- Establishment type on the cover
- Control Testing Laboratory
- FDA district office on the cover
- 8050 Marshall Drive, Suite 205 Lenexa, KS 66214
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
The accuracy, specificity and reproducibility of test methods have not been established and documented.
Specifically,
The accuracy, specificity, and reproducibility of DYNALABS "core" methods (DLMs) are developed using USP sourced active pharmaceutical ingredients (APis) and are not established for individual customer's unique finished dose drug formulations.
Your firm's management stated that all "core" DLMs were validated on USP-sourced API without using a customer-specific finished dose drug formulation in the validation work. This includes:
• Method Validation DLM <Redacted B4> Lidocaine HCl
• Method Validation DLM <Redacted B4> Epinephrine
• Method Validation DLM <Redacted B4> Triamcinolone Acetonide
A) The accuracy and specificity of your "core" DLMs do not assess the customer's formulated API in the presence of expected components such as excipients, degradants, or impurities that may be found in each customer's unique finished dose drug formulation. The lack of accuracy and specificity in "core" DLMs has led your firm to offer procedures such as <Redacted B4> and <Redacted B4> to all customers who have not paid for validation extensions, including 503B customers. ...
Observation 2
The written stability program for drug products does not include reliable, meaningful and specific test methods.
Specifically,
DYNALABS method extensions rely to <Redacted B4> studies performed on USP grade APis to support the Certificate of Analysis ("CoA") claim: <Redacted B4>" However, DYNALABS does not challenge actual finished dose drug product formulations in either the "core" method's <Redacted B4> study or in the method extension validation study used to support this claim.
For example, in the "core" method validation for DLM <Redacted B4> Moxifloxacin HCL, <Redacted B4> preparations of <Redacted B4> Solution <Redacted B4> ug.mL Moxifloxacin RS, sourced from USP) were prepared and exposed to various <Redacted B4> studies which included <Redacted B4>. In the method extension validation for Moxifloxacin HCl DLMJ <Redacted B4> for Sample Lot # <Redacted B4> one finished drug product sample was prepared and injected <Redacted B4> on the HPLC and only the %RSD and sample recovery was evaluated. A placebo lot provided by the customer was prepared in duplicate and stored in the customer's container/closure system. ...
Observation 3
Deviations from written specifications, standards, test procedures and laboratory mechanisms are not recorded and justified.
Specifically,
A) Microbiology analysts do not label plates with initials and correct dates. For example, plates due for pulling from incubation for reading may have the wrong date. On 9/13/19 and 9/18/19, a micro analyst at your firm was observed not following SOP/MIC 45, specifically: Plates were pre-labelled <Redacted B4> and <Redacted B4> , <Redacted B4> and "In: Mar 08" and "Out: Mar 13" by an analyst plating dilutions for <Redacted B4> . Testing on 9/13/19._Each plate observed had the incorrect "In:" and "Out:" dates for incubation. MIC 45 procedure step <Redacted B4> states "<Redacted B4". Furthermore, MIC 45 step <Redacted B4> states the analyst is to <Redacted B4> ." On 09/18/19, three plates were pre-labeled (1) "<Redacted B4>" and "In: 03/14", and <Redacted B4> , and "In: 03/14" and the <Redacted B4> " and "In: 03 14." Your firm could not provide a justificauon for using plates pre-labeled with Marctes, for testing that was initiated in September.
For example, plates due for pulling from incubation for reading may have the wrong date. ...
Observation 4
The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
Specifically,
The Quality Unit is deficient.
A) Decisions and deviations relating to testing are made without quality unit input, approval, or documentation. Your firm's management stated that laboratory management may communicate with customers through a Technical Services Representative, outside of the Quality unit, to discuss issues with laboratory testing and obtain customer approval for planned deviations, such as <Redacted B4> or <Redacted B4> (see Observation 1). For example, an email was sent to a customer on 3/22/19 regarding Lot# <Redacted B4> from a laboratory personnel to Marketing Technical Services stating <Redacted B4> " A Technical Services Representative replied, "Customer has approved the sample. Please result and close out." The Quality Unit was not involved in the communication and your firm's management stated that there is no documented procedure for this type of communication.
documented procedure for this type of communication.
B) Procedures for opening Deviations and initiating CAP As are not adequate. ...
Linked 483s whose text is not shown
- Oct 29, 2015: FDA document 86617: the FEI number and firm name on its cover do not match this page by the rule.
State board of pharmacy records
State board of pharmacy records for Missouri are not checked: the Division of Professional Registration’s license downloads sit on a script-driven portal, and its robots.txt file disallows the board’s pharmacy pages.
This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.